Advertisement

Topics

Dr. Reddy's Laboratories Announces USFDA Final Approval and Launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market

23:06 EDT 14 Jun 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching Buprenorphine and Naloxone Sublingual...

Other Sources for this Article

Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
SAUNAK SAVLA
saunaks@drreddys.com
(Ph: +91-40-49002135)
or
MEDIA RELATIONS
CALVIN PRINTER
calvinprinter@drreddys.com
(Ph: +91-40- 49002121)

NEXT ARTICLE

More From BioPortfolio on "Dr. Reddy's Laboratories Announces USFDA Final Approval and Launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...